Clinical trial
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs…
NCT00333359 · XenoPort, Inc., Industry · Completed
Key facts
| NCT number | NCT00333359 |
|---|---|
| Title | XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. |
| Official title | An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome. |
| Lead sponsor | XenoPort, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | XP13512 (GEn) |
| Enrollment | 581 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 5, 2006 |
| Last update posted | Jul 22, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: